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Structural variation (SV) is a significant component of the genetic etiology of both neurodevelopmental and psychiatric disorders; how-
ever, routine guidelines for clinical genetic screening have been established only in the former category. Genome-wide chromosomal
microarray (CMA) can detect genomic imbalances such as copy-number variants (CNVs), but balanced chromosomal abnormalities
(BCAs) still require karyotyping for clinical detection. Moreover, submicroscopic BCAs and subarray threshold CNVs are intractable,
or cryptic, to both CMA and karyotyping. Here, we performed whole-genome sequencing using large-insert jumping libraries to delin-
eate both cytogenetically visible and cryptic SVs in a single test among 30 clinically referred youth representing a range of severe neuro-
psychiatric conditions. We detected 96 SVs per person on average that passed filtering criteria above our highest-confidence resolution
(6,305 bp) and an additional 111 SVs per genome below this resolution. These SVs rearranged 3.8 Mb of genomic sequence and resulted
in 42 putative loss-of-function (LoF) or gain-of-function mutations per person. We estimate that 80% of the LoF variants were cryptic to
clinical CMA. We found myriad complex and cryptic rearrangements, including a ‘‘paired’’ duplication (360 kb, 169 kb) that flanks a
5.25 Mb inversion that appears in 7 additional cases from clinical CNV data among 47,562 individuals. Following convergent genomic
profiling of these independent clinical CNV data, we interpreted three SVs to be of potential clinical significance. These data indicate
that sequence-based delineation of the full SV mutational spectrum warrants exploration in youth referred for neuropsychiatric evalu-
ation and clinical diagnostic SV screening more broadly.Structural variation (SV) is a major component of the ge-
netic etiology of neurodevelopmental disorders. In recent
years, enrichment of large, de novo copy-number variants
(CNVs) and balanced chromosomal abnormalities (BCAs)
has been reported and replicated in youth with autism
spectrum disorder (ASD [MIM 209850]), developmental
delay (DD), and intellectual disability (ID).1–5 At present,
genetic testing is frequently included in diagnostic evalua-
tion of such youth, with chromosomal microarray (CMA)
serving as the recommended first-tier genetic screen since
2010 based on a consensus statement in this journal.6–8
For ASD, the use of CMA reflects the recognition that, in
addition to the subset of cases with clinical features that
can indicate a known genetic syndrome (e.g., Fragile X
[MIM 300624]), nonsyndromic cases may benefit from
genome-wide CNV evaluation.9 Nonetheless, despite rec-
ommendations that extend across the full autism spec-
trum, genetic testing is not pursued for all individuals.10
A significantly increased burden of large CNVs has also
been observed in psychiatric disorders, including attention
deficit hyperactivity disorder (ADHD [MIM 143465]),
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(MIM 125480).11–15 Notably, psychiatric and neurodeve-
lopmental conditions often co-occur,16 and findings for
both rare SVs and common polymorphic risk variants
suggest an overlapping etiology.17,18 There is no current
consensus on CMA or even general genetic testing for
psychiatric disorders, although its potential benefit in
this population has been discussed.19,20
Array-based technologies such as CMA can capture
relative dosage imbalances that are a consequence of
aneuploidy, CNV, and unbalanced translocation. In devel-
opmental disorders, the implementation of CMA as a
first-tier genome-wide screen has significantly improved
diagnostic yield over conventional karyotyping or gene-
based mutation screening. One study of 6,539 consecutive
referrals to Signature Genomics identified at least one clin-
ically significant CNV in 17.6%–22.5% of cases, depending
on the resolution of the array test performed (whole-
genome BAC versus oligonucleotide).21 In referrals for
whom no causal genetic lesion is detected, however, addi-
tional SV testing is rarely pursued for mutations that are
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of detection for a given technology), and the impact of
cryptic rearrangements is therefore unknown in this popu-
lation.With respect to BCAs, karyotyping remains the only
conventional diagnostic method capable of surveying
their presence, as illustrated in a recent prenatal diagnostic
comparison of CMA and karyotyping.22 Karyotyping
transformed human genetics more than half a century
ago by opening access to gross chromosomal changes
through microscopic visualization of alterations to chro-
mosome banding patterns. The method is limited to a res-
olution of ~5–10 Mb, depending on banding patterns
within the breakpoint regions, and has yet to be sup-
planted in diagnostic practice by higher-resolution
methods for BCA detection. Moreover, cryptic BCAs are
intractable to all conventional clinical genetic screening.
These BCAs are not measurable at karyotype resolution
or by CMA, and have not been delineated by whole-
exome sequencing (WES) or low-depth whole-genome
sequencing from the 1000 Genomes Project to date.23,24
The mutational spectrum of cryptic SVs (submicroscopic
BCAs and small CNVs) therefore represents a largely
uncharacterized source of potential loss-of-function (LoF)
mutations in biomedical research and a blind spot in
genetic diagnostics.
In a series of previous studies, we have shown that
whole-genome sequencing (WGS) using large inserts of
several kilobases (referred to herein as jumping libraries)
can delineate cytogenetically visible BCAs in both a
research capacity and prenatal diagnostic practice.5,25–28
These methods provide a single technology capable of de-
tecting both CMA-resolution CNVs and karyotype-resolu-
tion BCAs, as well as cryptic SVs. This approach thus allows
whole-genome detection of the full SV mutational spec-
trum at a time and cost comparable to CMA and karyo-
type.26 In the current study, we used this jumping library
sequencing approach to evaluate the presence and poten-
tial impact of both cytogenetically visible and cryptic chro-
mosomal aberrations in a clinically referred sample of
children and adolescents. Specifically, we sequenced youth
with a range of severe neuropsychiatric disorders (NPDs;
i.e., neurodevelopmental and psychiatric conditions)
whom we hypothesize are enriched for LoF variation.
Subjects were obtained through the Longitudinal Study
of Genetic Influences on Cognition (LOGIC), which col-
lects deep cognitive and psychiatric phenotyping and
DNA on youth referred for neuropsychiatric evaluation.
The study also collects abbreviated phenotypes and DNA
onfirst-degree relativeswhere possible.Our goal for the cur-
rent proof-of-concept project was the sequencing of ge-
nomes from 30 youth referred for clinical neuropsychiatric
evaluation. We selected 29 probands (ages 4–19) as well as
an affected sibling, an affected father, and a healthymother
from a four-member multiplex family (32 total subjects).
Specifically, we selected the 29 consecutive cases at the
time of analysis who had provided DNA via whole blood
(as opposed to saliva) and who manifested particular diag-
noses in order of our priorities. First, we prioritized individ-The Americuals with severe early-onset psychiatric presentations
reflecting the psychosis ormood disorder spectrum, regard-
less of their comorbidities (n ¼ 18; 62%). Second, we
included youth with other neuropsychiatric disorders
(i.e., autism spectrum and ADHD) and some evidence of se-
vere presentation (i.e., comorbidity, prior psychiatric hospi-
talization). As shown in Table S1 available online, a total of
25 youths met full diagnostic criteria for one or more psy-
chiatric conditions, and 7 of these met criteria for a comor-
bid neurodevelopmental disorder. Thus, more than half of
the sample (55%) had an exclusively psychiatric disorder
(see Table S1 for complete details). We note that only one
sample had previously undergone CMA analysis with no
significant variants detected, and no samples had been pre-
viously referred for targeted gene panel testing. All subjects
provided informed consent, and this study was approved
by the Institutional Review Board of Partners HealthCare.
Large-insert jumping libraries were generated using our
previously published protocols, which are provided in
complete detail in Hanscom and Talkowski.27 The method
generates genomic libraries in which short end reads
(25 base pairs in this study) are separated by long inserts
(targeted to 2.5 kb in this study), yielding very high
coverage of mapped inserts spanning the genome for
minimal sequencing cost. Following library preparation,
sequencing was performed on all samples on an Illumina
HiSeq 2000, generating a median insert size of 2.6 kb and
median insert coverage of 623 per library.27 Analysis of
large-insert jumping libraries leverages spatial relation-
ships of mated reads to trace distinctive breakpoint signa-
tures rather than relying upon coverage from the actual
nucleotides sequenced.25 Expanding upon our previous
methods to delineate karyotypically visible BCAs,25,28 for
this study we developed a SV classifier for WGS using
jumping libraries with a targeted emphasis on reducing
type I (false-positive) errors that can present a major barrier
to interpretation (see Figure S1 for details). In brief, we clus-
tered anomalously mapping read pairs across all samples
using BamStat and ReadPairCluster.25 We next computed
a set of metrics for each cluster based on its constituent
reads and properties of the genomic region spanned by
the cluster (see Figure S1). Each cluster was classified based
on thresholds calculated from a training set of PCR and
Sanger sequencing validated SVs. We executed this process
within a joint calling framework to mitigate false positive
variant classifications that are a consequence of reference
misassembly or systematic short read alignment errors
in regions with alignment biases (e.g., highly repetitive
regions such as segmental duplications). Across the ge-
nomes of our 29 probands, we identified 98 deletion, 43
tandem duplication, 99 inversion, and 112 interchromo-
somal insertion clusters that occurred in 90% or more of
probands, most of which appear to be systematic mapping
errors in complex genomic regions.
After excluding all reference variation and alignment
artifacts, we tested the precision of our classification algo-
rithm by investigating the inheritance of SV calls amongan Journal of Human Genetics 95, 454–461, October 2, 2014 455
Table 1. Counts of All Structural Variantsa
Event
Classifications
All SV
Observations
SV
Count
Private
SV Count
Polymorphic
SV Count
Deletions 3,234 622 318 304
Tandem
duplications
383 119 72 47
Inversions 888 112 26 86
Interchromosomal
insertions
701 80 21 59
Intrachromosomal
insertions
633 55 7 48
Complex
chromosomal
rearrangements
170 16 6 10
Total 6,009 1,004 450 554
aStructural-variant counts from large-insert sequencing after filtering for
mapping and reference artifacts.our four-member family. We performed the initial analyses
at a resolution approximately equal to themaximum insert
size of all samples that the BWA aligner will designate as
reads having a proper alignment (R6,305 bp in this study).
Subthreshold CNV detection is therefore unreliable as dele-
tions are indistinguishable from proper pairs below this
high-confidence resolution.29 In total, we identified 190
high-confidence SVs between both children, 188 (98.9%)
of which exhibited normal Mendelian inheritance upon
inspection of corresponding SV clusters in parents. We
observed two events in the proband and affected sibling
(a 6.5 kb interchromosomal insertion of chr9 into chr22
and a 90 kb deletion at 14q11.2) that were not in either
parent, but detected in at least one other unrelated sample
in our larger cohort. This suggests that these polymorphic
variants were not captured or filtered in the parent (false
negatives). We next considered balanced SVs smaller than
our high-confidence resolution of 6.3 kb. We identified an
additional 243 balanced SVs in the affected siblings. Of
these 243 subthreshold SVs, 95.5% followed normal Men-
delian inheritance, suggesting that our methods retain a
high level of precision below 6.3 kb resolution. The poten-
tial for type II errors (false negatives) is themajor limitation
of exploring SV below this size resolution, as SVs localized
entirely within a fragment insert cannot be detected by
our methods, and small BCAs can be missed based on sto-
chastic fluctuations in coverage. Therefore, while we do
detect many small balanced SV events, this is likely to be
a significant underestimate of the total SVs present in a
given genome below our highest-confidence resolution.
Sequencing in all probands identified a total of 650 var-
iants larger than the 6.3 kb high-confidence resolution
threshold (362 private, 288 polymorphic), resulting in a
median of 96 SVs per proband. We found an additional
354 variants (88 private, 266 polymorphic) below our
high-confidence resolution, resulting in an additional
111 SVs per proband. In sum, these events correspond
to 112 deletions, 13 tandem duplications, 31 balanced456 The American Journal of Human Genetics 95, 454–461, Octoberinversions, 24 interchromosomal insertions, 21 intrachro-
mosomal insertions, and 6 complex chromosomal rear-
rangements (CCRs; rearrangements with three or more
breakpoints) per average proband (Table 1). The majority
of the CCRs were cryptic to karyotyping and CMA, suggest-
ing that CCRs may be a more common phenomenon in
the viable human germline than previously appreciated.
For genome annotation, we investigated both LoF and
gain-of-function (GoF) mutations. Absent molecular char-
acterization of all variants, we adhered to the interpreta-
tion of previous exome-sequencing studies that classify a
LoF mutation as any variant that disrupts the protein cod-
ing sequence. While haploinsufficiency of RNA cannot be
confirmed without molecular evaluation, we have demon-
strated in our previous BCA sequencing and 16p11.2 tran-
scriptome sequencing studies that dosage compensation of
a gene in which a single copy is disrupted is rare.5,30 We
found an average of 25 LoF mutations per proband from
all SVs in this study that meet this definition. For the
purposes of this study and without access to material for
molecular confirmation, we nominally defined GoF in
this study as a copy gain of the entire gene, recognizing
that an increase in mRNA may not correspond to a molec-
ular gain of function; we observed this 17 times per
proband. Importantly, the vast majority of observed LoF
mutation (80%) would be cryptic to conventional CMA.
In these analyses, we used 100 kb as a conservative esti-
mate of CMA resolution, although many clinical CMA
studies have lower resolution on the genomic backbone
(e.g., it is approximately 240 kb on the SignatureChip
Oligo Solution array) and higher resolution in targeted
regions of known genomic disorders.31 On average, the
SVs detected result in 3.8Mb of rearranged DNA per person
(0.1% of haploid genome).
A limitation of WGS as compared to CMA is the ability
to detect CNVs in repetitive or misassembled genomic
regions, such as segmental duplications or microsatel-
lites. Given that several common genomic disorders are
a consequence of segmental-duplication-mediated non-
homologous allelic recombination (NAHR) (e.g., 16p11.2
deletion/duplication, 22q11.2 deletion syndrome32), we
performed a complementary focal insert-depth analysis
to survey genomic imbalance in these regions. Notably,
BCAs localized to highly repetitive regions remain unde-
tectable by this and all short-read sequencing methods.
We modified a pre-existing WGS read-depth algorithm
(cn.MOPS33) to accommodate insert coverage rather than
read depth. This modified method modeled normalized
insert depth alterations simultaneously across all samples
in 1, 3, 10, and 30 kb bins. We applied this insert-depth
calling approach to 88 genomic regions corresponding to
established genomic disorders already being investigated
in prenatal diagnostic testing22 and uncovered a 15q13.3
microduplication flanked by segmental duplications—
thus intractable to paired-end clustering alone—and previ-
ously identified as a duplication syndrome (Figure 1).34 We
confirmed this variant through microarray analysis of the2, 2014
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Figure 1. Focal Insert-Depth Compari-
son across All 33 Libraries Detects CNVs
Mediated by Segmental Duplication
Focal insert-depth analysis successfully
delineated CNVs in both the presence and
absence of paired-end cluster support.
Shown are a 1.55 Mb duplication with
paired-end clustering support (A) and a
432 kb duplication flanked by segmental
duplications (B) (orange) without pair-end
support. Insert depth was scaled by chro-
mosome-specific coverage within each
library before bin-wise normalization
across all libraries, yielding a t-score repre-
sentative of relative enrichment or deple-
tion in insert depth for each sample as
compared to the entire cohort (plotted in
thick line above). Blue highlights bins that
achieved nominal significance (p% 0.05).
Light yellow shading corresponds to a
cn.MOPS duplication call. Gray shaded re-
gions reflect variability of insert depth by
position (dashed line: median t-score; dark
gray: t-score MAD; light gray: 2 * t-score
MAD). Bins were analyzed at multiple sizes
(1, 3, 10, and 30 kb).same case (Birdsuite35 LOD score 545.6). It was present in a
14-year-old male with average range intellectual func-
tioning, pervasive developmental disorder not otherwise
specified (PDD-NOS), and clinically impairing but fluctu-
ating anxiety (anxiety disorder, not otherwise specified).
The 15q13.3 microduplication syndrome has been associ-
ated with these psychiatric conditions in addition to major
depressive disorder (MDD [MIM 608516]), ADHD, obses-
sive-compulsive disorder (OCD [MIM164230]), and alcohol
abuse (MIM 103780)34,36 and is not fully penetrant in the
population. 36,37
We found that a significant subset of the duplications
observed involve insertion of a copy at a distant site, rather
than being tandemduplications (9.9%above our high-con-
fidence threshold in this cohort). One striking example in-
volves two independent duplications on the same chromo-
some in a 19-year-oldwith ASD and ID, detectable by CMA,
on 15q25 (360.3 kb) and 15q26 (169 kb) that flank a
5.25 Mb inversion, disrupting AKAP13 (MIM 604686) and
IQGAP1 (MIM 603379) (Figure 2). We investigated duplica-
tion signatures at 15q25 and 15q26 in array CNV data from
theDatabaseofGenomicVariation38 (DGV) andan internal
CNV database of 33,573 independent cases sourced from
clinical diagnostic laboratories and 13,989 controls from
GWAS microarrays.5 We detected 7 individuals with a
similar duplication signature as our subject, suggesting
that these subjects may harbor the same cryptic inversion.
Interpretation of rare, private mutation remains a signif-
icant challenge inhumangenetic researchandclinical diag-
nostics. To annotate detected genic disruptions in theThe American Journal of Human Geabsence of molecular characteriza-
tion,we performed two stages of inter-
pretation. In the first, we used thecriteria established by Wapner et al.22 for clinically signifi-
cant SVs in prenatal diagnosis. This analysis required an
SV tomeet at least one of the following criteria to be consid-
ered pathogenic: (1) SVwithin or overlapping a targeted re-
gion fromanestablishedgenomicdisorder, (2) SVof 1Mbor
greater size not inherited from an unaffected parent, or (3)
SV that disrupts a gene implicated in an autosomal-domi-
nant Mendelian or X-linked disorder. Notably, these ana-
lyses encompass many of the criteria described for CMA
testing of ASD or ID. Based upon these criteria, we found
one likely pathogenic SV (the 15q13.3 duplication
described above).We did not interpret the 5.3Mb inversion
flanked by ‘‘paired’’ duplications as pathogenic as it was in-
herited fromanunaffectedmother, and itsmolecular signif-
icance therefore warrants further investigation.
The second stage of interpretation investigated only LoF
variants with disruptions of at least one coding exon in a
gene previously associated with NPDs and required a
nominally significant CNV burden from cases with neuro-
developmental disorders obtained from clinical diagnostic
laboratories compared to controls (total n ¼ 47,562). This
convergent genomic approach was previously described
in detail (see Talkowski et al.).5 We PCR-validated all puta-
tively significant SVs in probands and available parental
DNA; as above, we required any LoF variant passing these
criteria to not be inherited from an unaffected parent.
Considering these criteria, we found two additional private
SVs to be potential NPD risk factors based upon disruption
of a gene previously associatedwithNPDs and analyses that
revealed a nominally significant increased CNV burdennetics 95, 454–461, October 2, 2014 457
Figure 2. Inversion Signature Marked by
Two Tandem Duplications
SV sequencing revealed clusters of inverted
read-pairs 5.25Mbapart (top). The inverted
segment contains duplicated regions at
each breakpoint (360 kb, 169 kb). Subse-
quent analysis of insert depth (at bottom)
revealed a duplication signature easily
detectable by CMA. We investigated a
collection of CNV data from 47,562 indi-
viduals and identified 7 additional cases
who display this same ‘‘paired’’ duplica-
tions signature (blue bars), suggesting the
presence of an inverted segment between
the two CNVs in these cases.(Table 2). The first was a deletion of NKD2 (MIM 607852;
CNV burden p ¼ 0.03) in a 12-year-old female diagnosed
with MDD, anxiety disorder not otherwise specified, and
borderline intellectual functioning. This variant has been
previously associated with ASD.39 The second was disrup-
tion of UBE2F (CNV burden p ¼ 8.3 3 104) in a 12-year-
old male who met diagnostic criteria for multiple
conditions (i.e., bipolar disorder with psychotic features,
Asperger syndrome, generalized anxiety disorder, and
ADHD, variant previously associated with ASD40). Both of
these youths had a history of psychiatric hospitalization
and parents with anxiety and mood diagnoses. Taken
together with the 15q13.3 duplication, these represent
three likely pathogenic variants among the 29 probands
in our study (10.3%), two of which were cryptic to CMA.
We also discovered three private variants that represent
potentially novel NPD loci and warrant further study. One
is a 130.9 kb duplication of chromosome 1p34.2 with a
nominally significant increased CNV burden. A second is
a 44 kb deletion on chromosome 19 that deletes ZNF57
and the first three exons of ZNF77 (MIM 194551). The final
variant detected is a complete deletion of exon 15 of
SLC23A2 (MIM 603791), which encodes sodium-ascorbate
cotransporter 2, a key cellular transporter of vitamin C41
that has not previously been implicated in NPDs. Neurons
deficient for SLC23A2 exhibit reduced activity and neurite
growth,42 a finding further supported by animal studies
that have indicated vitamin C modulates both learning
and memory.43 Another variant detected lies in the pro-
moter region of RBFOX1 (MIM 605104), which encodes
a neuron-specific splicing factor involved with neuronal
excitation44 and has been implicated in a range of NPDs
including intellectual disability,45 ASD,46,47 and ADHD.48
This 58 kb deletion was present in all affected members
of our four-member family and thus appeared to segregate
with NPDs. However, when we scrutinized available
convergent genomic data for RBFOX1 from our clinical
diagnostic CNV cohort, we found no evidence that dosage458 The American Journal of Human Genetics 95, 454–461, October 2, 2014alterations of this locus represent an
NPD risk factor (p%0.995). Similar re-
sults have beenpreviously observed in
control cohorts.49 Of these patho-genic or notable variants detected in our SV screen, four of
the six SVs (66.7%) would be cryptic to CMA.
There are limitations to interpretation of these findings.
The sample size for this proof-of-concept study is small.
Much larger cohorts are required to robustly establish esti-
mates of cryptic SVs and clinical diagnostic yield from such
populations. The jumping library method, as with all
short-read sequencing approaches, is limited to detection
of the portion of the human genome that can be uniquely
aligned by short reads; SVs in highly repetitive regions are
largely intractable to these methods and are not accounted
for in this study. Further, our particular approach applied
stringent filtering of SV clusters based on thresholds
derived from validated variants in our training set. These
data suggest that the method performed well in reducing
false-positive SVs, but this was probably at a cost of
increased false-negative results. Future studies in much
larger samples and access to very deep WGS using long-
read technologies will greatly improve upon these initial
estimates of cryptic SVs.
Taken together, these data provide insight into the land-
scape of cryptic SVs in clinically referred youth with severe
NPDs, including youth with purely psychiatric conditions
and youth with developmental disorders who have not
previously been referred for genetic testing. We find that
balanced and cryptic SVs represent an important and yet
uncharacterized component of the genetic architecture of
NPDs and warrant exploration in standard evaluation
of severe psychiatric presentations in clinically referred
youth. Moreover, our analyses establish that innovative
sequencing approaches are capable of detecting patho-
genic SVs that are currently detectable by CMA, as well
as those that are cryptic to conventional technologies yet
represent an important fraction of LoF mutation in a given
genome. These data suggest that cost-effective WGS may
represent a higher-resolution alternative testing modality
to CMA or karyotyping for genome-wide SV assessment
in clinical practice.
Table 2. Variants with Nominally Significant Support from Convergent Genomic Data Sets
CNV Type
Position Phenotypea
Gene(s) Disrupted
CNV Burden
Chr Start (Mb) Stop (Mb) Size (kb) Proband NDD Control p Valueb
Del 5 1.00 1.05 48.4 MDD, ANX-NOS, bIQ NKD2 23 7 0.03
Del 19 2.90 2.94 44.2 BPD, ADHD ZNF57, ZNF77c 6 0 0.04
Dup 2 238.87 238.88 10.7 BPD w/ psychotic features,
AS, GAD, ADHD
UBE2F 17 1 0.001
Dup 1 40.18 40.31 130.9 MDD, ANX-NOS BMP8B,d OXCT2,e
PPIE, TRIT1
15 3 0.02
Del 20 4.93 4.97 40.8 ID, features of ADHD and ASD SLC23A2 12 1 0.01
aPhenotype abbreviations: All diagnoses are based on criteria for the Diagnostic and Statistical Manual of Mental Disorders – Fourth Edition (DSM-IV). MDD, major
depressive disorder; ANX-NOS, anxiety disorder, not otherwise specified; bIQ, borderline IQ; BPD, bipolar disorder; AS, Asperger syndrome; GAD, generalized
anxiety disorder; ADHD, attention-deficit/hyperactivity disorder; ID, intellectual disability; ASD, autism spectrum disorder.
bFisher’s exact test p values are provided for CNV burden.
cMIM 602284.
dGene with reported CNV burden; MIM 610289.
eMIM 602435.Supplemental Data
Supplemental Data include one figure and 1 table and can be
found with this article online at http://dx.doi.org/10.1016/j.
ajhg.2014.09.005.
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Web Resources
The URLs for data presented herein are as follows:
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cn.MOPS, http://www.bioinf.jku.at/software/cnmops/
Online Mendelian Inheritance in Man (OMIM), http://www.
omim.org/
R statistical software, http://www.r-project.org/
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Accession Numbers
All sequencing data reported in these 32 subjects have been depos-
ited in the National Database for Autism Research (NDAR acces-
sion: http://ndar.nih.gov/study.html?id¼357).
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